Company provides additional management updates

Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, today announced that key proposals needed to carry out the company’s strategic transformation were approved by shareholders at its annual meeting held on June 30, 2025.

The approved proposals included the issuance of equity as a form of payment pursuant to Tivic’s worldwide exclusive license agreement for Entolimod™ and Entolasta™, including for uses in acute radiation syndrome, neutropenia and other indications in oncology and hematology. Shareholders also approved the Company’s issuance of equity in accordance with previously announced financing arrangements. In each case, Tivic was required to obtain shareholder approval under Nasdaq listing rules.

“We have established a strong foundation for Tivic’s expansion into biopharmaceutical markets -- starting with commercialization of Entolimod for two large-market indications,” stated Tivic CEO, Jennifer Ernst. “We have already received strong customer interest in Entolimod’s national defense applications as a potential treatment for acute radiation syndrome. We have also secured exclusive rights for its use in the treatment of neutropenia, a market currently estimated to reach nearly $21 billion worldwide by 2032.”

Leadership Update

“I am also pleased to announce that Lisa Wolf, who has served as our Interim Chief Financial Officer for the last nine months and in senior leadership roles on Tivic’s finance team for more than three years, yesterday assumed the official role of our permanent Chief Financial Officer,” said Ernst. “Lisa has been instrumental in supporting the financial architecture of our expansion and I look forward to continuing to work closely with her through this exciting period.

“I also want to thank, Blake Gurfein, who served as our Chief Scientific Officer for eight years, spearheading the development and commercialization of ClearUP, our first FDA-approved product, and our expansion into our Vagus Nerve Stimulation program. I look forward to continuing to work with Blake as he steps down from his CSO role and assumes a consultant role with Tivic, in which he will continue to support the VNS program, including product and intellectual property development.”

About Tivic Health Systems, Inc.

Tivic Health seeks to treat underserved medical conditions through biochemical and bioelectric therapies that modulate patients’ immune system. The company's lead biopharma product candidate, the TLR5 agonist Entolimod™ to treat ARS, has been granted Fast Track and Orphan Drug designation by the FDA. Tivic Health's bioelectronic program is developing non-invasive medical devices that personalize key stimulation to modulate the pathways implicated in many prevalent and debilitating diseases.

Tivic Health's first FDA approved product ClearUP™ is proven to treat sinus pain and pressure, and is available through online retailers and commercial distributors. For more information about Tivic Health, visit: https://ir.tivichealth.com

Forward-Looking Statements

This press release may contain “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems, Inc.’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including as a result of the company’s interactions with and guidance from the FDA and other regulatory authorities; changes to the company’s relationship with its partners; failure to obtain FDA or similar clearances or approvals and noncompliance with FDA or similar regulations; the company’s future development of its ncVNS treatment, Entolimod and Entolasta; changes to the company’s business strategy; timing and success of clinical trials and study results, including the ncVNS optimization study with The Feinstein Institute of Bioelectronic Medicine; regulatory requirements and pathways for approval; changes in the markets and industries in which the company does business; consummation of any strategic transactions; the company’s need for, and ability to secure when needed, additional working capital; the company’s ability to maintain its Nasdaq listing; and changes in tariffs, inflation, legal, regulatory, political and economic risks. Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of risks and uncertainties relevant to the company, and other important factors, see Tivic Health’s filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 21, 2025, under the heading “Risk Factors”, as well as the company’s subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and the company undertakes no duty to update such information except as required by applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250708263695/en/